Pharmaceutical

Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics’s TN-401?

TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy.

Dec 15, 2024 - 06:00
TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Forte Bioscien...

Next Article

Risk adjusted net present value: What is the current valuation of Solid Bioscien...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Sanders wants NIH to adopt ‘reasonable pricing’ language for drugs that agency research helps develop

STAT+: Sanders wants NIH to adopt ‘reasonable pricing’ ...

Jun 14, 2023

STAT+: Once bullish on digital health, Orexo hits a wall on reimbursement

STAT+: Once bullish on digital health, Orexo hits a wal...

Apr 29, 2023

STAT+: Pharmalittle: Lilly expects Medicare to back down on Alzheimer’s drug coverage; key senators change insulin cap proposal

STAT+: Pharmalittle: Lilly expects Medicare to back dow...

Apr 21, 2023